Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and PK of 14C-radiolabeled ACT-132577 in Healthy Males
NCT03100591Phase 1Completed
- Sponsor
- Idorsia
- Start
- Mar 2017
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aprocitentan in hypertension (HTN), sponsored by Idorsia. Primary endpoint: Cumulative excretion of radioactivity in urine and feces at Day 15. Started Mar 2017; status: completed.
02
Drugs
aprocitentan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03100591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03100591.